Activity of flurbiprofen and chemically related anti-inflammatory drugs in models of Alzheimer's disease.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Brain research. Brain research reviews

• Publication date

  2005-04-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/J.BRAINRESREV.2004.12.029PMID 15850679
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Transgenic AD model mice, effects of potential anti-AD treatments on inflammation and pathology.

  2005cited by this paper
• Lack of Specific Amyloid-β(1-42) Suppression by Nonsteroidal Anti-Inflammatory Drugs in Young, Plaque-Free Tg2576 Mice and in Guinea Pig Neuronal Cultures

  2005cited by this paper
• Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration.

  2004cited by this paper
• S- but not R-enantiomers of flurbiprofen and ibuprofen reduce human microglial and THP-1 cell neurotoxicity.

  2004cited by this paper
• Non‐steroidal anti‐inflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action

  2004cited by this paper
• Comparison between Flurbiprofen and its Nitric Oxide-Releasing Derivatives HCT-1026 and NCX-2216 on Aβ(1-42)-Induced Brain Inflammation and Neuronal Damage in the Rat

  2004cited by this paper
• Gastric Tolerability and Prolonged Prostaglandin Inhibition in the Brain with a Nitric Oxide-Releasing Flurbiprofen Derivative, NCX-2216 [3-[4-(2-Fluoro-α-methyl-[1,1′-biphenyl]-4-acetyloxy)-3-methoxyphenyl]-2-propenoic acid 4-nitrooxy butyl ester]

  2004cited by this paper
• Microglial activation facilitates A B plaque removal following intracranial antiA B antibody administration

  2004cited by this paper
• Rofecoxib

  2004cited by this paper
• Passive Amyloid Immunotherapy Clears Amyloid and Transiently Activates Microglia in a Transgenic Mouse Model of Amyloid Deposition

  2004cited by this paper
• Attenuation of chronic neuroinflammation by a nitric oxide‐releasing derivative of the antioxidant ferulic acid

  2004cited by this paper
• Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease.

  2004cited by this paper
• Evidence supporting a role for anti-Aβ antibodies in the treatment of Alzheimer’s disease

  2004cited by this paper
• Modulation of β‐amyloid metabolism by non‐steroidal anti‐inflammatory drugs in neuronal cell cultures

  2003cited by this paper
• Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies

  2003cited by this paper
• Novel anti-inflammatory therapy for Parkinson's disease.

  2003cited by this paper
• Inflammatory processes in Alzheimer's disease.

  2003cited by this paper
• Anti-Inflammatory Drug Therapy Alters β-Amyloid Processing and Deposition in an Animal Model of Alzheimer's Disease

  2003cited by this paper
• Intracranially Administered Anti-Αβ Antibodies Reduce β-Amyloid Deposition by Mechanisms Both Independent of and Associated with Microglial Activation

  2003cited by this paper
• Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization

  2003cited by this paper
• The influence of brain inflammation upon neuronal adenosine A2B receptors

  2003cited by this paper
• The development of COX2 inhibitors

  2003cited by this paper
• Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.

  2003cited by this paper
• Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation.

  2003cited by this paper
• NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo

  2003cited by this paper
• Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease.

  2003cited by this paper
• NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo.

  2003cited by this paper
• Pharmacologic agents associated with a preventive effect on Alzheimer's disease: a review of the epidemiologic evidence.

  2002cited by this paper
• Selective inhibition of Abeta42 production by NSAID R-enantiomers.

  2002cited by this paper
• Neuroinflammation in Alzheimer's disease and prion disease

  2002cited by this paper
• Selective inhibition of Aβ42 production by NSAID R‐enantiomers

  2002cited by this paper
• Microglial Activation and β-Amyloid Deposit Reduction Caused by a Nitric Oxide-Releasing Nonsteroidal Anti-Inflammatory Drug in Amyloid Precursor Protein Plus Presenilin-1 Transgenic Mice

  2002cited by this paper
• Inflammation in neurodegenerative disease--a double-edged sword.

  2002cited by this paper
• Inhibition of NF‐KB and AP‐1 activation by R‐ and S‐flurbiprofen 1, 2

  2001cited by this paper
• A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity

  2001cited by this paper
• Inhibition of NF-kappaB and AP-1 activation by R- and S-flurbiprofen.

  2001cited by this paper
• The Curry Spice Curcumin Reduces Oxidative Damage and Amyloid Pathology in an Alzheimer Transgenic Mouse

  2001cited by this paper
• Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice.

  2001cited by this paper
• Protection against β‐amyloid peptide toxicity in vivo with long‐term administration of ferulic acid

  2001cited by this paper
• Differential effects of the nonsteroidal antiinflammatory drug flurbiprofen and its nitric oxide‐releasing derivative, nitroflurbiprofen, on prostaglandin E2, interleukin‐1β, and nitric oxide synthesis by activated microglia

  2001cited by this paper
• Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease.

  2001cited by this paper
• Cellular and molecular basis of b-amyloid precursor protein metabolism (Y2K update)

  2000cited by this paper
• Ibuprofen Suppresses Plaque Pathology and Inflammation in a Mouse Model for Alzheimer's Disease

  2000cited by this paper
• Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

  2000cited by this paper
• Cellular and molecular basis of beta-amyloid precursor protein metabolism.

  2000cited by this paper
• CELLULAR AND MOLECULAR BASIS OF β-AMYLOID PRECURSOR PROTEIN METABOLISM

  2000cited by this paper
• Inflammation and Alzheimer's disease.

  2000cited by this paper
• The effects of a novel NSAID on chronic neuroinflammation are age dependent.

  1999cited by this paper
• Peripheral administration of novel anti-inflammatories can attenuate the effects of chronic inflammation within the CNS.

  1999cited by this paper
• A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease

  1999cited by this paper
• Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse

  1999cited by this paper
• Indomethacin Reverses the Microglial Response to Amyloid β-Protein

  1998cited by this paper
• Indomethacin reverses the microglial response to amyloid beta-protein.

  1998cited by this paper
• A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes.

  1997cited by this paper
• Nonsteroidal anti-inflammatory drugs in Alzheimer's disease

  1995cited by this paper
• Reduction of gastrointestinal injury in acute endotoxic shock by flurbiprofen nitroxybutylester.

  1995cited by this paper
• Clinical trial of indomethacin in Alzheimer's disease

  1993cited by this paper

• Synthesis of Novel (S)-Flurbiprofen-based Esters for Cancer Treatment by Targeting Thymidine Phosphorylase via Biomolecular Approaches

  2024cites this paper
• HSV-1 cellular model reveals links between aggresome formation and early step of Alzheimer’s disease

  2023cites this paper
• Chiral resolution of (±)-flurbiprofen using molecularly imprinted hydrazidine-modified cellulose microparticles.

  2023cites this paper
• Synthetic Transformation of 2-{2-Fluoro[1,1′-biphenyl]-4-yl} Propanoic Acid into Hydrazide–Hydrazone Derivatives: In Vitro Urease Inhibition and In Silico Study

  2022cites this paper
• Separation and identification of a complex flurbiprofen-polyethylene glycol mono- and diester mixture via a hyphenated HPLC-DAD-HRMS/SPE NMR system.

  2022cites this paper
• New Pharmaceutical Cocrystal Forms of Flurbiprofen: Structural, Physicochemical, and Thermodynamic Characterization

  2019cites this paper
• Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.

  2018cites this paper
• Phytochemicals from Achillea fragrantissima are Modulators of AβPP Metabolism

  2018cites this paper
• Integrated communications between cyclooxygenase‐2 and Alzheimer's disease

  2018cites this paper
• Synthesis of L-Ascorbyl Flurbiprofenate by Lipase-Catalyzed Esterification and Transesterification Reactions

  2017cites this paper
• Pharmaceutical and in vitro therapeutic equivalence studies of ketoprofen enteric coated 100 mg tablets.

  2017cites this paper
• 8.09 – Verubecestat

  2017cites this paper
• Novel NSAID-Derived Drugs for the Potential Treatment of Alzheimer’s Disease

  2016cites this paper
• Flurbiprofen axetil increases arterial oxygen partial pressure by decreasing intrapulmonary shunt in patients undergoing one-lung ventilation

  2015cites this paper
• New organic nitrate-containing benzyloxy isonipecotanilide derivatives with vasodilatory and anti-platelet activity.

  2015cites this paper
• Cognitive Enhancers and Treatments for Alzheimer's Disease

  2015cites this paper
• Pharmacological effects of Ibuprofen on learning and memory, muscarinic receptors gene expression and APP isoforms level in pre-frontal cortex of AlCl3-induced toxicity mouse model

  2015cites this paper
• Enantioseparation of Racemic Flurbiprofen by Aqueous Two-Phase Extraction With Binary Chiral Selectors of L-dioctyl Tartrate and L-tryptophan.

  2015cites this paper
• Effect of C5a/C5aR on Glutamate Receptors and Glutamate Transporters expression in AD model mice

  2014cites this paper
• New Functions of Old Drugs: Aureolic Acid Group of Anti- Cancer Antibiotics and Non-Steroidal Anti-Inflammatory Drugs

  2014cites this paper
• Combination therapy in a transgenic model of Alzheimer's disease.

  2013cites this paper
• Amyloid beta-induced glycogen synthase kinase 3β phosphorylated VDAC1 in Alzheimer's disease: implications for synaptic dysfunction and neuronal damage.

  2013cites this paper
• Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay

  2013cites this paper
• Metabolism and Pathways for Denitration of Organic Nitrates in the Human Liver

  2013cites this paper
• Comparative Interactome Investigation of γ-secretase Complex in Alzheimer’s Disease

  2013cites this paper
• Disease-Modifying Therapies in Alzheimer’s Disease

  2012cites this paper
• Flurbiprofen.

  2012cites this paper
• Lipase-catalyzed alcoholytic resolution of (R,S)-flurbiprofenyl azolides for preparation of (R)-NO-flurbiprofen ester prodrugs

  2011cites this paper
• Complement in the brain.

  2011cites this paper
• Switching the Microglial Harmful Phenotype Promotes Lifelong Restoration of Subtantia Nigra Dopaminergic Neurons from Inflammatory Neurodegeneration in Aged Mice

  2011cites this paper
• gamma-Secretase as a therapeutic target in Alzheimer's disease.

  2010cites this paper
• Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease

  2010cites this paper
• Nitric oxide: target for therapeutic strategies in Alzheimer's disease.

  2010cites this paper
• Efecto de las manipulaciones genéticas y farmacológicas sobre la actividad del complejo gamma-secretasa

  2010cites this paper
• Von der symptomatischen zur kausalen Therapie?

  2009cites this paper
• Enantioseparation of flurbiprofen on amylose-derived chiral stationary phase by supercritical fluid chromatography.

  2009cites this paper
• Fluorescence and mass spectrometry studies of the interaction between naproxen and synthetic pseudopeptidic models in organic media

  2009cites this paper
• Pharmacokinetic and bioequivalence comparison between orally disintegrating and conventional tablet formulations of flurbiprofen: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male volunteers.

  2009cites this paper
• NO‐flurbiprofen reduces amyloid‐β, is neuroprotective in cell culture, and enhances cognition in response to cholinergic blockade

  2009cites this paper
• Retinoid X receptor‐α mediates (R )‐flurbiprofen’s effect on the levels of Alzheimer’s β‐amyloid

  2009cites this paper
• Flurbiprofen derivatives in Alzheimer's disease: synthesis, pharmacokinetic and biological assessment of lipoamino acid prodrugs.

  2008cites this paper
• Interactions between APP secretases and inflammatory mediators

  2008cites this paper
• Regulation of Glial Cell Functions by PPAR-γ Natural and Synthetic Agonists

  2008cites this paper
• Validation of a nonaqueous capillary electrophoretic method for the enantiomeric purity determination of R-flurbiprofen using a single-isomer amino cyclodextrin derivative.

  2008cites this paper
• Beta-amyloid and glutamate receptors.

  2008cites this paper
• Non-cholinergic drug development for Alzheimer's disease

  2008cites this paper
• Protective effects of NSAIDs on the development of Alzheimer disease

  2008cites this paper
• Emerging amyloid beta (Ab) peptide modulators for the treatment of Alzheimer's disease (AD)

  2008cites this paper
• Macrophages, Microglia, and Dendritic C

  2008cites this paper
• Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease.

  2008cites this paper
• Multiple functions of generic drugs: future perspectives of aureolic acid group of anti-cancer antibiotics and non-steroidal anti-inflammatory drugs.

  2008cites this paper
• It May Take Inflammation, Phosphorylation and Ubiquitination to ‘Tangle’ in Alzheimer’s Disease

  2007cites this paper
• Lipopolysaccharide-induced cerebral inflammatory damage and the therapeutic effect of platelet activating factor receptor antoganist

  2007cites this paper
• Binary polymeric blends to microencapsulate nitroflurbiprofen: physicochemical and in silico studies.

  2007cites this paper
• Lipopolysaccharide-induced cerebral inflammatory damage and the therapeutic effect of platelet activating factor receptor antoganist

  2007cites this paper
• Identification of flurbiprofen and its photoproducts in methanol by gas chromatography-mass spectrometry.

  2007cites this paper
• Biochemical aspects of inflammation

  2007cites this paper
• Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice

  2007cites this paper
• An update on pharmacological approaches to neurodegenerative diseases

  2007cites this paper
• γ-Secretase: a complex target for Alzheimer's disease

  2007cites this paper
• Gamma-secretase: a complex target for Alzheimer's disease.

  2007cites this paper
• Donepezil: an update

  2007cites this paper
• Mitochondrial Oxidative Damage in Aging and Alzheimer's Disease: Implications for Mitochondrially Targeted Antioxidant Therapeutics

  2006cites this paper
• Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease

  2006cites this paper
• Molecular Properties of Flurbiprofen and its Solid Dispersions with Eudragit RL100 Studied by High- and Low-Resolution Solid-State Nuclear Magnetic Resonance

  2006cites this paper
• Dynamic regulation of microglial functions by the non-steroidal anti-inflammatory drug NCX 2216: implications for chronic treatments of neurodegenerative diseases.

  2006cites this paper
• Is there a Future for Cyclo-Oxygenase Inhibitors in Alzheimer’s Disease?

  2006cites this paper
• Cerebral amyloidoses: molecular pathways and therapeutic challenges.

  2006cites this paper
• New pathways in drug discovery for alzheimer’s disease

  2006cites this paper
• Potential Claims for Rheumatoid Arthritis Reduction in signs and symptoms of RA Major clinical response Complete clinical response Remission Prevention of disability

  2006cites this paper
• Pharmacological strategies for the prevention of Alzheimer’s disease

  2006cites this paper
• Can herbs provide a new generation of drugs for treating Alzheimer's disease?

  2005cites this paper
• Dynamic Complexity of the Microglial Activation Response in Transgenic Models of Amyloid Deposition: Implications for Alzheimer Therapeutics

  2005cites this paper
• Clinical aspects of inflammation in Alzheimer's disease

  2005cites this paper